Docetaxel (XRP6976)

DRUG7 trials

Conditions

Gastric CancerHead and Neck NeoplasmsNeoplasm MalignantNeoplasm MetastasisNeoplasm Recurrence, LocalProstate CancerProstate Cancer MetastaticProstatic Neoplasms

Phase 1

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

CompletedNCT01148615

SanofiNeoplasm Malignant

Start: 2010-07-31End: 2011-12-31Updated: 2012-01-13

Phase 2

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

CompletedNCT00401323

SanofiHead and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Start: 1998-01-31End: 2003-06-30Updated: 2011-01-20

Japanese Study of the Combined Administration of Docetaxel With Prednisolone for Metastatic Hormone Refractory Prostate Cancer

CompletedNCT00723086

SanofiTherapy, Prostatic Neoplasms

Start: 2005-05-31End: 2008-09-30Updated: 2009-10-01

Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

CompletedNCT01576029

SanofiProstatic Neoplasms

Start: 2012-08-31End: 2013-12-31Updated: 2013-12-24

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

CompletedNCT01718353

SanofiProstate Cancer Metastatic

Start: 2013-03-31End: 2015-08-31Updated: 2017-11-20

Phase 3

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

CompletedNCT01308567

SanofiProstate Cancer

Start: 2011-05-05End: 2018-05-31Updated: 2019-06-05

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer

CompletedNCT01515748

SanofiGastric Cancer

Start: 2011-12-30End: 2021-12-13Updated: 2023-12-13

2025-03-014 citations

Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA

JCO Clinical Cancer Informatics2024-02-166 citations

Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.

JCO Global Oncology2023-08-011 citations

Neoadjuvant docetaxel, oxaliplatin, and s-1 plus surgery and adjuvant s-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial.

Journal of Clinical Oncology2023-06-0114 citations

Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

Contemporary Clinical Trials Communications2021-11-091 citations

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Journal of Clinical Oncology2021-06-16327 citations

Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies

The Oncologist2021-04-274 citations

An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.

2021-03-167 citations

Abstract LB-270: Discovery of genomic correlates and tumor purity as an independent clinical factor of poor outcome in advanced prostate cancer lpWGS CNA data

Cancer Research2020-08-151 citations

Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.

Journal of Clinical Oncology2019-05-202 citations

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY

Clinical Cancer Research2018-10-09113 citations

Post hoc responder analysis of health‐related quality of life (HRQL) in patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials

Annals of Oncology2018-10-01

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

2018-02-2881 citations

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

Journal of Clinical Oncology2017-07-28350 citations

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer

Journal of Clinical Oncology2017-06-2081 citations

AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY.

Journal of Clinical Oncology2017-02-20

Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).

Journal of Clinical Oncology2016-05-2053 citations

TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2016-05-205 citations

Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).

Journal of Clinical Oncology2016-05-204 citations

A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY).

Journal of Clinical Oncology2015-05-207 citations

2 more papers not shown

Docetaxel (XRP6976)

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers